Landos Biopharma

Landos Biopharma: Lanthionine Synthetase C-Like 2 (LANCL2) is a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Successfully raised $60MM Series B in August 2019 with Perceptive and RTW.

Sector/Industry:

Healthcare/Biotechnology

Characteristics:

Based in...

US - South Atlantic

Clinical Stage

Phase l or ll

Disease Space

Autoimmune, Gastrointestinal, Metabolic Disorders

Listing

Public, USA

Market Cap

100MM - 500MM

Website:

http://www.landosbiopharma.com/

Profiles:

Address:

1800 Kraft Drive SW
Suite 216
Blacksburg, VA 24060
United States

Presentation:

Please reach out to Solebury Trout to request a presentation

More info:

Send Message to Request Information

My account:

Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13

Josep Bassaganya-Riera, President & CEO

Lead Programs

BT-11

Indication	Phase
LANCL2	2
LANCL2	1

NX-13

Indication	Phase
NLRX1	IND
NLRX1	IND

BT-104

Indication	Phase
LANCL2	Pre-clinical
LANCL2	Pre-clinical

Top 10 Holders of Landos Biopharma, Inc.

Institution	OS (%)	Position	Mkt Val ($MM)	Source	Filing Date
RTW Investments LP	12.51	4,900,722	55.23	Stakes	2/8/21
JPMorgan Investment Management, Inc.	0.63	245,176	2.76	Funds	2/28/21
The Vanguard Group, Inc.	0.15	59,384	0.67	Funds	2/28/21
Geode Capital Management LLC	0.05	18,662	0.21	Funds	2/28/21

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.